La cadena de opciones muestra datos clave de las opciones de acciones de Cassava Sciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cassava Sciences..

Cassava Sciences (NASDAQ:SAVA) Bolsa, Cadena de Opciones

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

SAVANNAH ENERGY PLC by Savannah Energy Plc

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

The ongoing U.S.-China trade dispute may find resolution through the reported appointment of special envoys by Presidents&nbsp;Donald Trump and Xi Jinping.&nbsp;This could pave the way for better communication channels, analysts suggest.
What Happened: The U.S. and China are grappling with how to restart trade talks. While the Chinese have proposed the concept of special envoys, the U.S. is reluctant, favoring direct negotiations between Trump and Xi. However, the Chinese view this proposal as &#8220;risky and uncertain&#8221;, the South China Morning Post reported <a href="https://www.scmp.com/news/china/diplomacy/article/3308919/us-china-trade-stand-ease-negotiators-must-be-agreed-upon-analysts">on</a> Saturday.
Chinese experts based in Washington believe that appointing special envoys from both countries could help address and stabilize the strained relationship.
The situation is further complicated by a dispute regarding China&#8217;s role in supplying ingredients used in the illicit production of fentanyl, a powerful opioid. This led to Trump imposing a 20%&nbsp;tariff on Chinese products in&nbsp;a previous round of duty increases.
As per a Wall Street Journal report <a href="https://www.wsj.com/world/china/beijing-weighs-fentanyl-offer-to-u-s-to-start-trade-talks-287cf233">on</a> Friday, China may use the fentanyl issue as a lever for trade talks or as a bargaining chip in future negotiations. The report also hints that China might send Minister for Public Security Wang Xiaohong to the U.S. to kickstart discussions.
Eurasia Group&#8217;s Jeremy Chan told SCMP, "Beijing is hoping to use fentanyl cooperation as either a catalyst for US-China trade talks or a bargaining chip in a future round of negotiations, rather than a goodwill gesture ahead of trade talks as Trump's team has called for.&#8221;
Why It Matters:&nbsp;This development comes in the wake of China&#8217;s Commerce Ministry &#8216;<a href="https://www.benzinga.com/25/05/45160145/china-says-door-is-open-for-talks-while-it-is-assessing-us-trade-proposal-but-warns-coercion-and-extortion-wont-work">assessing</a>&#8216; a U.S. offer to discuss the crippling 145% tariffs imposed by President Donald Trump on Friday. China expressed its readiness to engage in discussions but insisted that the U.S. must be prepared to rectify &#8220;erroneous practices&#8221; and revoke unilateral tariffs.
On Sunday, President Trump stated that his primary objective was to secure a fair trade agreement with China. While speaking to reporters aboard Air Force One, he mentioned that he had no plans to talk with Chinese President Xi Jinping this week. However, he added that U.S. officials were in discussions with their Chinese counterparts on a range of issues.
Earlier, <a href="https://www.benzinga.com/markets/25/04/45065482/us-china-to-ease-tariffs-gradually-after-complex-talks-says-morgan-stanley-but-cuts-chinas-growth-outlook">economists</a> at Morgan Stanley projected that both nations would begin negotiations and gradually decrease tariffs on Chinese imports to 60% by the end of Q2. However, tariffs are not expected to revert to their pre-January 25 levels.
More in-depth talks in the second half of the year could further lower tariffs on Chinese imports to 34% by the end of 2025, indicating the abolition of the 20% fentanyl-related tariff.
On Friday, U.S.-listed Chinese stocks PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), and Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) climbed 4.67%, 4.34%, and 2.33%, respectively, after China showed openness to U.S. trade talks.
READ MORE:
<ul>
<li><a href="https://benzinga.com/markets/25/05/45183000/warren-buffetts-right-hand-man-greg-abel-is-quietly-taking-over-day-to-day-leadership-at-berkshire-hathaway-gotten-much-more-involved-in-capital-allocation-decisions" target="_blank" rel="noreferrer noopener">Warren Buffett&#8217;s Right-Hand Man Greg Abel Is Quietly Taking Over Day-To-Day Leadership At Berkshire Hathaway: &#8216;Gotten Much More Involved In Capital Allocation Decisions&#8217; &#8211; Benzinga</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

News

Global

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

China Pushes For Special Envoys As Direct Deal With Trump Deemed 'Risky', Plans Fentanyl Concessions As Negotiating Leverage: Report

Collaboration to leverage Akamai's proven Tactical ICAM capabilities and P3M Works' UK government expertise to secure third-party access and supply chain operations

AKAM

Akamai And P3M Launch Zero Trust ICAM Partnership To Safeguard UK Government And Defense Networks

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index was in the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled higher on Friday following the release of jobs data, with the S&amp;P 500 recording gains for the ninth consecutive day to notch its longest winning streak since Nov. 2004.
All three major averages recorded gains for the second week, with the S&amp;P 500 adding 2.9% and the Dow gaining 3% on the week. The Nasdaq, meanwhile, closed higher by 3.4% for the week.
On the economic data front, nonfarm payrolls rose by 177,000, beating expectations of 130,000 and easing concerns over tariff-related hiring slowdowns. The unemployment rate remained unchanged at 4.2%, as expected. New orders for U.S.-manufactured goods, meanwhile, rose by 4.3% to $618.8 billion in March.
DuPont de Nemours Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) shares rose on Friday after the company's first-quarter 2025 results topped Wall Street estimates.
Most sectors on the S&amp;P 500 closed on a positive note, with financial, communication services, and industrials stocks recording the biggest gains on Friday. However, health care and consumer staples stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 564 points to 41,317.43 on Friday. The S&amp;P 500 gained 1.47% to 5,686.67, while the Nasdaq Composite climbed 1.51% to 17,977.73 during Friday's session.
Investors are awaiting earnings results from Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>), Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), and Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 42.6, the index was in the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 41.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:<a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

S&P 500 Notches Longest Win Streak In Over 2 Decades: Investor Sentiment Improves, Greed Index In 'Fear' Zone

Representative Marjorie Taylor Greene (R-Ga.) recently voiced her dissatisfaction over the current direction of U.S. foreign and domestic policies in a lengthy post on X.
What Happened:&nbsp;Greene took to X on Friday to express her concerns about the U.S.&#8217;s potential involvement in a war with Iran and the recent U.S.-Ukraine minerals deal. 
She stated that the Donald Trump administration is becoming disconnected from its base and failing to follow through on its promises.
Greene criticized the continued approval of the COVID-19 vaccine despite reported side effects, and called for accountability for &#8220;law fair&#8221;&nbsp;waged against the American people&nbsp;in the past four years.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I represent the base and when I'm frustrated and upset over the direction of things, you better be clear, the base is not happy. I campaigned for no more foreign wars. And now we are supposedly on the verge of going to war with Iran. I don't think we should be bombing foreign…
&mdash; Rep. Marjorie Taylor Greene&#x1f1fa;&#x1f1f8; (@RepMTG) <a href="https://twitter.com/RepMTG/status/1918351681374581181?ref_src=twsrc%5Etfw">May 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Greene stated, &#8220;I represent the base and&nbsp;when I'm frustrated and upset&nbsp;over the direction of things,&nbsp;you better be clear, the&nbsp;base is not happy.&#8221; She questioned the wisdom of engaging in foreign wars and the recent minerals deal with Ukraine, which she claimed was a repayment for U.S. aid misused by Ukraine.
Expressing dissatisfaction, she stated, "Why don't we just mine our own rare earth minerals that are tied up on federal lands that the government confiscated years ago?"
She also criticized Republicans for their inaction on election integrity and transgender issues, emphasizing the frustration felt by her supporters.
Greene wrapped up her long post, stating, &#8220;And Trump isn't on the ballot in the future, so do the math on that.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/05/45187216/bitcoin-ethereum-dogecoin-slide-as-traders-turn-cautious-before-fed-meeting-analyst-foresees-btc-correction-to-86000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Slide As Traders Turn Cautious Before Fed Meeting: Analyst Foresees BTC &#8216;Correction&#8217; To $86,000 &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fractional undivided be</a>
Why It Matters: Rep. Marjorie Taylor Greene, a prominent supporter of President Trump, has now openly criticized the Trump administration, in a rare move.
Greene&#8217;s comments come in the wake of recent developments in U.S. foreign policy. The U.S. and Ukraine recently <a href="https://www.benzinga.com/25/04/45123271/us-ukraine-sign-minerals-deal-scott-bessent-says-agreement-is-a-clear-sign-to-russia-that-trump-administration-wants-a-free-and-prosperous-kyiv">signed a deal </a>to invest in Ukraine's mineral resources, oil, and gas sectors, a move seen as a key support for Ukraine and a signal to Russia of the U.S. commitment to a free and prosperous Ukraine.
Moreover, President Donald Trump <a href="https://www.benzinga.com/government/regulations/25/05/45149446/oil-prices-soar-after-trump-threatens-sanctions-on-iranian-crude-buyers-is-china-on-top-of-the-list">threatened sanctions </a>on nations purchasing Iranian oil and petrochemicals, causing a sharp rise in oil prices.&nbsp;
Greene&#8217;s comments reflect the concerns of a significant portion of the American populace, indicating a growing divide in the country&#8217;s political landscape.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45185750/dont-piss-down-my-back-and-tell-me-its-raining-says-dave-portnoy-this-is-trumps-market-not-bidens" target="_blank" rel="noreferrer noopener">&#8216;Don&#8217;t Piss Down My Back And Tell Me It&#8217;s Raining,&#8217; Says Dave Portnoy—&#8217;This Is Trump&#8217;s Market, Not Biden&#8217;s&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Rep. Marjorie Taylor Greene 'Frustrated And Upset' With The Trump Administration, Questions US Foreign Policy: 'You Better Be Clear, The Base Is Not Happy'

<ul>
<li>Financing follows&nbsp;completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.</li>
</ul>

Inventiva Secures €116M Second Tranche From €348M Financing To Advance Lanifibranor In MASH

<ul>
<li>Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIA</li>
<li>FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025</li>
</ul>

LQDA

Reported Friday, Liquidia Clears Legal Hurdle As Court Dismisses United Therapeutics' Challenge To PH-ILD Indication

ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ON/earnings">opening bell on Monday, May 5.</a>
Analysts expect the Scottsdale, Arizona-based company to report quarterly earnings at 50 cents per share, down from $1.08 per share in the year-ago period. ON Semiconductor projects to report quarterly revenue at $1.4 billion, compared to $1.86 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 14, ON Semiconductor announced it ceased efforts to acquire Allegro MicroSystems and withdrew its all-cash proposal of $35.10 per share after determining there was "no actionable path forward."
ON Semiconductor shares gained 5.8% to close at $41.91 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ON/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Tore Svanberg maintained a Hold rating and lowered the price target from $52 to $42 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Christopher Danely maintained a Neutral rating and cut the price target from $52 to $40 on April 11, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Keybanc analyst John Vinh maintained an Overweight rating and cut the price target from $60 to $55 on April 8, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and cut the price target from $71 to $62 on March 24, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Needham analyst Quinn Bolton reiterated a Buy rating with a price target of $57 on March 3, 2025. This analyst has an accuracy rate of 77%.</li>
</ul>
Considering buying ON stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05025753/image-2-11-1024x588.png" alt="" class="wp-image-900682" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05025753/image-2-11-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05025753/image-2-11-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05025753/image-2-11-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05025753/image-2-11.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

ON Semiconductor Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

As Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) <a href="https://www.benzinga.com/markets/equities/25/03/44067763/goodbye-skype-microsoft-teams-takes-over-offering-free-calls-and-more">bids farewell</a> to Skype today, May 5, the move marks not just the end of an internet era but a major turning point in the company's communication strategy — and for investors who believed in Microsoft back in 2011, when it acquired the platform, it's been a profitable ride.
What Happened: Microsoft is officially shutting down Skype after more than two decades of service, encouraging users to migrate to Microsoft Teams, its modern communication and collaboration platform.
Launched in 2003, Skype became a digital lifeline for families, friends and businesses worldwide. Its familiar ringtone and video call interface were once synonymous with global connectivity.
See Also:&nbsp;<a href="https://www.benzinga.com/25/04/45093311/not-everyone-needs-a-thousand-ai-engineers-but-for-those-who-do-zuckerberg-says-meta-will-gladly-build-it-for-a-price" target="_blank" rel="noreferrer noopener">Meta CEO Mark Zuckerberg Says AI Won&#8217;t Just Be About Free Tools And Ads — Some People Will Pay A Fortune To Deploy Armies Of Digital Workers</a>
However, as mobile-first and cloud-native platforms gained popularity, Skype struggled to keep up.
Microsoft acquired <a href="https://www.benzinga.com/news/asset-sales/11/05/1070323/microsoft-may-return-to-glory-days-with-8-5-billion-purchase-of-skype">Skype on May 10, 2011, for $8.5 billion</a>, aiming to bolster its presence in the consumer and enterprise communication space. Over time, it became clear that Skype's aging architecture was ill-suited for the demands of modern, integrated digital workspaces.
With Skype's retirement, Microsoft is signaling that Teams is now the company&#8217;s unified communications platform going forward.
$1,000 Then, Nearly $22,000 Now: While Skype's story is ending, Microsoft's growth has only accelerated in the years since the acquisition.
If you had invested $1,000 in Microsoft stock on the day it acquired Skype in 2011, you'd now be sitting on about $21,972.71. That investment would have bought you roughly 50.48 shares, factoring in Microsoft's history of stock splits.
Microsoft's share price has soared over the past decade as it successfully pivoted to cloud computing, productivity software and enterprise services — a strategy that included, but ultimately evolved beyond, Skype.
In the past five years, the share prices of Microsoft have up by 135.69% and year-to-date, it has gained by 3.99%, according to the data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. During Friday's regular hours, Microsoft shares closed at $435.28.
What's Next for Users: Skype users don't need to panic. Microsoft has ensured that transitioning to Teams is simple. By logging into Microsoft Teams with the same credentials, users will find their old Skype messages and contacts automatically synced.
The new platform includes all the familiar features — one-on-one calls, group chats, messaging — plus additional tools like integrated calendars, file storage, and community channels.
For paid Skype users, services will continue until current billing cycles end, and Skype Numbers can still receive calls through Teams or the Skype web portal.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/07/39842841/charlie-munger-said-getting-rich-is-harder-than-ever-but-heres-the-beauty-of-it-you-only-have-to" target="_blank" rel="noreferrer noopener">Charlie Munger Said Getting Rich Is Harder Than Ever, But Here's ‘The Beauty Of It' — You Only Have To Do It Once</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with&nbsp;the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was&nbsp;reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Tech

MSFT

Skype Is Officially Retiring Today — If You'd Invested $1,000 When Microsoft Bought It In 2011, Here's What You'd Be Sitting On Now

SMRT

Reported Friday, SmartRent Receives NYSE Notice For Noncompliance With Minimum $1 Share Price Requirement

Reported Friday, Arizona Complete Health Secures Six-Year Contract To Lead Arizona Long Term Care Medicaid Services

The Company also announced a special dividend to shareholders of Class A common stock of $0.10 per share, which totals approximately $0.3 million in the aggregate. The regular dividend, distribution, and the special dividend will be paid on June 25, 2025. The Record Date is May 15, 2025.

Dividends

MKTW

Reported Friday, MarketWise Announced $0.20 Regular Dividend Plus $0.10 Special Dividend, Payable June 25

Personal‑finance coach Dave Ramsey has a blunt message for workers fretting over market swings and shrinking 401(k) balances: your paycheck, not Wall Street headlines, is the real lever of wealth.
What Happened: In an <a href="https://www.thestreet.com/retirement/dave-ramsey-bluntly-warns-americans-on-401ks-market-swings">interview</a> with The Street, Ramsey said Americans still view employer‑sponsored 401(k)s and IRAs as the backbone of retirement security, especially when matched contributions stretch every dollar. 
But the bestselling author and popular call-in radio show personality warned that <a href="https://www.benzinga.com/personal-finance/24/12/42746966/debt-and-broke-are-the-norm-says-dave-ramsey-explains-why-normal-isnt-working-for-most-americans-and-how-to-take-control-of-your-money">debt and sloppy budgeting</a> choke off the cash needed to invest. "Your most powerful wealth‑building tool is your income," he said, urging households to craft a zero‑based budget before each month begins.
Ramsey's recipe is straightforward: hammer down debt, funnel freed‑up cash <a href="https://www.benzinga.com/money/what-is-a-401k">into a 401(k)</a> and Roth IRA, and let broad‑based mutual funds compound over decades. "No one wins on accident," he added. &#8220;Winning is an intentional act, whether it&#8217;s in your marriage, raising kids&#8230;. It&#8217;s an intentional act&#8230;&#8221;
See also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45166652/dave-ramsey-tells-couple-with-300000-income-they-are-broke-people-refuses-to-help-heres-why">Dave Ramsey Tells Couple With $300,000 Income They Are &#8216;Broke People&#8217;, Refuses To Help: Here&#8217;s Why</a>
<h3 class="wp-block-heading">Ramsey Says &#8216;Turn Off The TV&#8217;</h3>
Market turbulence, he argued, is mostly noise. During the COVID‑era sell‑offs, investors who stayed the course saw retirement balances rebound quickly. "Turn off the TV," Ramsey advises. &#8220;I&#8217;m a long-term investor,&#8221; Ramsey mentions. &#8220;So, the short-term temper tantrums I&#8217;m not going to get involved in.
Analysts at Fidelity note that 401(k) participation <a href="https://www.fidelity.com/about-fidelity/Q4-2024-retirement-analysis#:~:text=b)%20retirement%20accounts.-,According%20to%20the%20latest%20retirement%20data%20from%20Fidelity%20Investments%C2%AE,the%20fourth%20quarter%20of%202021." target="_blank" rel="noopener">remains very high</a> even as inflation <a href="https://www.benzinga.com/personal-finance/24/10/41213012/dave-ramseys-bold-plan-to-fight-inflation-could-his-radical-approach-help-you-keep-more-cash-in-">squeezes paychecks</a>, a sign that workers still bet on tax‑deferred growth over time. Ramsey's bottom line: Live on less than you make, automate contributions, and ignore the daily market drama. &#8220;If you learn to live on less than you make, and you learn to invest and you stay out of debt and you do it with a plan — those are the keys of people that actually become wealthy,&#8221; he said.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/25/04/45056965/dave-ramsey-says-doctors-and-lawyers-are-like-actors-notoriously-bad-with-money-just-because-you-make-a-lot-doesnt-mean-youre-winning" target="_blank" rel="noreferrer noopener">Dave Ramsey Says Doctors And Lawyers Are Like Actors, Notoriously Bad With Money — ‘Just Because You Make A Lot Doesn't Mean You're Winning'</a>

Financial Advisors

Personal Finance

Dave Ramsey Blasts Budget Slackers Who Bail On 401(k)s During Market Turmoil: 'Short‑Term Temper Tantrums'

UMAC

Reported Friday, Unusual Machines Announced Proposed Public Offering To Fuel U.S. Drone Parts Expansion

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) to report quarterly earnings at 82 cents per share on revenue of $13.14 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Tyson Foods shares rose 0.7% to $61.23 in after-hours trading.</li>
<li>Analysts expect Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) to post quarterly earnings at $4.90 per share on revenue of $8.19 billion. The company will release earnings before the markets open. Cummins shares rose 1% to $302.75 in after-hours trading.</li>
<li>TransCode Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) announced a 1-for-28 reverse stock split. TransCode Therapeutics shares dipped 27.8% to $0.37 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Before the markets open, Henry Schein Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is projected to report quarterly earnings at $1.11 per share on revenue of $3.23 billion. Henry Schein shares gained 1.3% to close at $65.30 on Friday.</li>
<li>Analysts expect Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) to post quarterly earnings at 2 cents per share on revenue of $36.20 billion after the closing bell. Ford shares slipped 0.1% to $10.27 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

HSIC

RNAZ

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday

After the S&amp;P 500 notched a nine-day winning streak on Friday, it sparked a debate among market experts. While some believe that it could be a precursor to a recession, others vehemently disagree, citing historical data to support their arguments.
What Happened: The Founder and President of Rosenberg Research &amp; Associates Inc., David Rosenberg, highlighted the rarity of such streaks and their historical association with recessionary periods.
According to Rosenberg, a consecutive nine-day streak has occurred only 0.25% of the time in the past century. Labeling it as a &#8220;3 sigma event,&#8221; he claimed that &#8220;80% of the time this dynamic happened in recessionary environments …not to mention just ahead of the October 1987 crash!&#8221; This led him to question the current &#8220;bullish&#8221; market sentiment.
However, Ryan Detrick from Carson Research countered this in a May 5 post, calling it &#8220;simply wrong/lazy analysis&#8221;. According to him, such nine-day streaks have occurred only three times during a recession out of the total 29 nine-day streaks since 1928.
This starkly contradicts Rosenberg&#8217;s claim of an 80% correlation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;When you are a hammer, everything looks like a nail.&quot; No, this is not true and simply wrong/lazy analysis meant to scare investors. Spending about 10 minutes (and using totally free data) showed that only 3 times out of 29 nine-day win streaks happened in a recession. <a href="https://t.co/uli58D9rDM">https://t.co/uli58D9rDM</a> <a href="https://t.co/26LIshCJqw">pic.twitter.com/26LIshCJqw</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1919192463274545464?ref_src=twsrc%5Etfw">May 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/05/45187070/warren-buffett-retires-after-decades-of-dominancefrom-tim-cook-to-mark-cuban-worlds-top-business-leaders-react-to-the-investment-icons-exit">&#8216;Curtain Call For The Captain:&#8217; Tim Cook, Bill Gates, Mark Cuban And Other Top Business Leaders React As Warren Buffett Bows Out</a>
Why It Matters: This rare winning streak from the S&amp;P 500 follows a complex economic backdrop. While investors assess the potential of a future rate cut and inflation, consumer spending and corporate earnings data have been positive.
However, the contradicting views from Detrick and Rosenberg underscore the challenge in predicting market movements, as the historical data can never help in developing definitive conclusions but just offer some insight into old patterns.
After the end of the nine-day streak, the S&amp;P 500 index was out of the correction zone, just down 7.5% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 8.33% lower than its 52-week high of 45,073.63 points and Nasdaq 100 was 9.54% lower than its previous high of 22,222.61 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Friday. The SPY was up 1.48% to $566.76, while the QQQ advanced 1.48% to $488.83, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
The futures of Dow Jones, S&amp;P 500, and Nasdaq 100 were trading lower on Monday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/05/45187563/apple-plans-major-iphone-launch-overhaul-with-biannual-release-schedule-starting-2026-report">Apple To Split iPhone Launches Starting 2026, Foldable Model May Debut With iPhone 18 Pro: Report</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Economics

S&P 500's 9-Day Climb Not A Recession Signal, Argue Analysts Amid Conflicting Research: 'Simply Wrong/Lazy Analysis'

Textron Aviation Delivers King Air 360C To Greece, Strengthening Air Ambulance Reach Across Remote Regions

<ul>
<li>Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer</li>
<li>Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]</li>
<li>Median Local Progression-Free Survival of 13.3 months from completion of radiation</li>
<li>Notable findings observed in exploratory biomarker analyses include:
<ul>
<li>An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS</li>
<li>CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS</li>
</ul>
</li>
<li>First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing</li>
<li>Investigators concluded that these results support further evaluation in a randomized study</li>
</ul>

NBTX

Nanobiotix Highlights Median 13.3-Month Local Progression-Free Survival With JNJ-1900 (NBTXR3) After Radiation

<ul>
<li>In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.</li>
<li>Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.</li>
<li>At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.</li>
<li>The early safety profile of REC-4881 was generally consistent with that of prior MEK1/2 inhibitors; among 19 patients across Phase 1b and 2, most treatment-related adverse events were Grade 1 or 2, with Grade 3 events in 16% of patients and no Grade ≥4 TRAEs reported to date.</li>
</ul>

RXRX

Reported Sunday, Recursion's REC-4881 Shows 43% Median Polyp Reduction In Phase 1b/2 FAP Study At Week 13 Assessment

<ul>
<li>This marks the second bulk order for the FX Super One MPV (Multi-purpose vehicle) in a one-week span and signifies the strong market demand and momentum for the FX brand and its lineup of new vehicles.</li>
<li>A total number of 1,300 units through non-binding pre-orders marks the continuous breakthroughs of B2B co-creation ecosystem model.</li>
<li>Non-binding fleet pre-orders have now been completed in both the East Coast and West Coast markets signifying National interest in the FX vehicle lineup. Both non-refundable deposits have been received.</li>
</ul>

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Reported Earlier, Faraday Future's FX Brand Secures Second Pre-Order With 300 FX Super One MPVs From Sky Horse Auto

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate program addressing two attractive target molecules in cancer medicine. The Company will utilize OmniAb's suite of transgenic antibody discovery solutions to source high-quality human antibody leads, which are naturally optimized through in vivo affinity maturation. VERAXA will subsequently establish the bsADC lead candidate by applying its proprietary linker technology and conjugation routine and will be responsible for preclinical validation. The resulting bsADC program will be jointly owned by both parties. Both parties will share any future revenues resulting from the program's continued development, licensing and commercialization.

OABI

VACH

VERAXA Biotech Joins Forces with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

Press Releases

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Legal

Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Health Care

General

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Management

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Comments

Cassava Sciences

Cassava Sciences (SAVA) Opciones

Cassava Sciences (NASDAQ:SAVA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL